Dr. Olga Kubassova Discusses AI in Medical Research and Drug Development on Forbes Podcast
In a recent Forbes podcast, Dr. Olga Kubassova, CEO of IAG, Image Analysis Group, shared groundbreaking insights on how artificial intelligence is revolutionizing clinical trials and drug development. This discussion is a must-listen for pharmaceutical and biotech leaders looking to optimize their R&D processes.
Key Takeaways for Drug Developers:
-
Structured Real-Time Data: Learn how IAG’s approach to data management can significantly reduce decision-making timelines in your clinical trials.
-
Modern Trial Infrastructure: Discover how DYNAMIKA, IAG’s proprietary cloud-based platform, can streamline your clinical operations and enhance data quality.
-
Smart Technologies: Explore how AI-driven imaging analysis can provide early efficacy assessments, potentially saving millions in development costs.
-
Risk Mitigation: Understand how IAG’s predictive analytics can help de-risk your clinical development process.
-
Accelerated Time-to-Market: Hear how IAG’s innovative approaches have helped bring lifesaving therapies to patients faster.
Dr. Kubassova’s insights come at a crucial time when the pharmaceutical industry is seeing a 700% increase in the use of imaging in clinical trials over the past decade. IAG’s expertise in this rapidly growing field could be the key to giving your drug development program a competitive edge.
Don’t miss this opportunity to learn how IAG’s cutting-edge solutions can transform your clinical trials. Listen to the full podcast on Forbes Books, Apple, or Spotify.
For more information on how IAG can accelerate your drug development process, contact imaging.experts@ia-grp.com.